1838 / 1851
RT + new drugs
1. Combination strategies not universally
associated with increased risks
2. All combinations need to be evaluated
individually
3. Different half-life of targeted therapy
(range 24 h – 50d)
|
|
1838 / 1851
RT + new drugs
1. Combination strategies not universally
associated with increased risks
2. All combinations need to be evaluated
individually
3. Different half-life of targeted therapy
(range 24 h – 50d)